Key result
BNT162b2 vaccine linked to rare severe myositis with mRNA detected in muscle one month post-vaccination.
Why the study?
Although the BNT162b2 COVID-19 mRNA vaccine is effective and safe, adverse events have been reported, prompting characterization of rare presentations such as severe myositis.
Can the BNT162b2 COVID-19 mRNA vaccine induce severe myositis in a previously healthy individual?
Case Report (n=1)
No
Can the BNT162b2 COVID-19 mRNA vaccine induce severe myositis in a previously healthy individual?
This case report provides clinical and molecular evidence of a rare, severe case of myositis associated with the BNT162b2 mRNA COVID-19 vaccine.
Rare myositis case post-BNT162b2 warrants vigilance in symptomatic patients; leaves open causality and incidence.
Initial clinical trials and surveillance data have shown that the most commonly administered BNT162b2 COVID-19 mRNA vaccine is effective and safe. However, several cases of mRNA vaccine-induced mild to moderate adverse events were recently reported. Here, we report a rare case of myositis after injection of the first dose of BNT162b2 COVID-19 mRNA vaccine into the left deltoid muscle of a 34-year-old, previously healthy woman who presented progressive proximal muscle weakness, progressive dysphagia, and dyspnea with respiratory failure. One month after vaccination, BNT162b2 vaccine mRNA expression was detected in a tissue biopsy of the right deltoid and quadriceps muscles. We propose this case as a rare example of COVID-19 mRNA vaccine-induced myositis. This study comprehensively characterizes the clinical and molecular features of BNT162b2 mRNA vaccine-associated myositis in which the patient was severely affected.
No takes yet. Share an insight, caveat, or question.
Magen et al. (2022) conducted a case report in COVID-19 vaccine-associated myositis (n=1). BNT162b2 COVID-19 mRNA vaccine was evaluated on Detection of BNT162b2 vaccine mRNA expression in tissue biopsy. The BNT162b2 COVID-19 mRNA vaccine was associated with a rare case of severe myositis in a 34-year-old woman, with vaccine mRNA expression detected in muscle tissue one month post-vaccination.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: